EUVIMEDEUVIMED entdecken
Crossref

Propranolol monotherapy in angiosarcoma – A window-of-opportunity study (PropAngio)

Alaa Embaby, Kimberley M Heinhuis, Nikki S IJzerman, Anne Miek Koenen, Stephanie van der Kleij, Ingrid Hofland, Hester van Boven, Joyce Sanders, Winette T A van der Graaf, Rick L Haas, Alwin D R Huitema, Winan J van Houdt und 1 weitere

European Journal of Cancer · 2024-05 · 202 · 113974

DOI: 10.1016/j.ejca.2024.113974 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024-05. Verfasst von Alaa Embaby und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands; Department of Clinical Pharmacology,…. Hauptthemen laut MEDLINE: Propranolol, Hemangiosarcoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Anticancer Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Angiosarcoma is a rare and aggressive cancer of the endothelial cells. Propranolol, a non-selective β-blocker, was able to initiate apoptosis in angiosarcoma cell lines and its anti-tumor activity has been described in several case reports. The aim of this trial was to prospectively evaluate the anti-tumor activity of propranolol monotherapy in patients with angiosarcoma before proceeding to standard of care treatment. METHODS: Propranolol was dosed 80 mg to 240 mg/day for 3 to 6 weeks according to a dose titration schedule. The primary endpoint was clinical response (response according to RECIST 1.1 or stable disease with improvement of cutaneous lesions) in at least three patients. Exploratory objectives included histologic response (>30% decrease in Ki-67), FDG PET response, and β-receptor expression levels. RESULTS: Fourteen patients were enrolled. The median duration of treatment was 26 days (range 21-42 days). The median highest propranolol dose was 160 mg/day (range 80 - 240 mg). Two patients showed clinical response (14%, 95% CI 3-100%). One of these patients showed a partial metabolic response on PET-CT. None of the tumors showed histologic response. The most common adverse event was grade 1/2 bradycardia (86%). There were no grade ≥ 3 adverse events. ADRB2 was overexpressed in 16 out of 18 tumors, in both responders and non-responders. None of the tumors showed ADRB1 overexpression. CONCLUSIONS: This window-of-opportunity trial did not show clinical efficacy of propranolol monotherapy. However, two out of 14 patients did show clinical benefit. ADRB1/2 expression did not correlate with clinical response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PropranololHemangiosarcomaHumansPositron Emission Tomography Computed TomographyEndothelial CellsAdrenergic beta-Antagonists

Stichwörter der Autor:innen

AngiosarcomaBeta-blockadeClinical researchPropranololSoft tissue sarcomaTranslational research

Substanzen

PropranololAdrenergic beta-Antagonists

Autor:innen und Institutionen

  • Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands; Department of Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, N…
  • Department of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.
  • Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.
  • Department of Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands.
  • Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam,…
  • Department of Radiotherapy, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.

Förderung

  • Anticancer Fund

Zitieren

APA

Embaby, A., Heinhuis, K. M., IJzerman, N. S., Koenen, A. M., van der Kleij, S., Hofland, I., van Boven, H., Sanders, J., van der Graaf, W. T. A., Haas, R. L., Huitema, A. D. R., van Houdt, W. J., & Steeghs, N. (2024). Propranolol monotherapy in angiosarcoma – A window-of-opportunity study (PropAngio). European Journal of Cancer, 202, 113974. https://doi.org/10.1016/j.ejca.2024.113974

Vancouver

Embaby A, Heinhuis KM, IJzerman NS, Koenen AM, van der Kleij S, Hofland I, et al. Propranolol monotherapy in angiosarcoma – A window-of-opportunity study (PropAngio). European Journal of Cancer. 2024;202:113974. doi:10.1016/j.ejca.2024.113974

BibTeX
@article{Embaby2024,
  author = {Embaby, Alaa and Heinhuis, Kimberley M and IJzerman, Nikki S and Koenen, Anne Miek and van der Kleij, Stephanie and Hofland, Ingrid and van Boven, Hester and Sanders, Joyce and van der Graaf, Winette T A and Haas, Rick L and Huitema, Alwin D R and van Houdt, Winan J and Steeghs, Neeltje},
  title = {Propranolol monotherapy in angiosarcoma – A window-of-opportunity study (PropAngio)},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {202},
  pages = {113974},
  doi = {10.1016/j.ejca.2024.113974}
}
Kostenlos starten →